Lapachol, a naphthoquinone discovered in 1858, is a natural product with a broad spectrum of therapeutic activities, along with its derivatives and analogues. Initially found in several species of the Bignoniaceae family, lapachol can also be found in other families. Lapachol arouses great interest and knowledge due to its crucial role in medicinal chemistry, playing an important role in the rational planning of research in search of bioactive substances with pharmacological action, whether as a source of raw material or helping directly or indirectly. This work aims to describe a new methodology for extracting lapachol, which differs from the conventional acid-base method, providing a highly efficient, simple and easy-to-apply process. 1858 activities analogues family families chemistry action indirectly acidbase acid base method efficient easytoapply easy apply process 185 18 1

The mangosteen (Garcinia mangostana, Linn.) is a tropical fruit cultivated in the tropical forests of Southeast Asian countries. It is recognized as the queen of fruits due to its unique color, aroma, and flavor. It has been used for centuries in Southeastern Asian traditional medicine for the treatment of various diseases. Many functional molecules with high medicinal value are obtained from the pericarp of mangosteen fruit, whose major constituent is xanthone α-mangostin. Several studies have been carried out over the last decades to further investigate and understand the pharmacological properties associated with the plant and its main chemical constituents, belonging to the class of xanthones. In addition, numerous in vitro and in vivo studies related to mangosteen have been published, indicating its importance and its potential application in medicinal chemistry. Prenylated xanthones, which include α-mangostin, are secondary metabolites particularly common in plants belonging to the Clusiaceae family. These substances have been intensively investigated for their potential as biologically active agents. This article describes a critical analysis of published data related to the properties of α-mangostin, aiming to provide a more detailed view of its potential as a chemotherapeutic agent for the prevention and treatment of infectious diseases. Garcinia mangostana Linn. Linn countries color aroma flavor diseases αmangostin. αmangostin α mangostin. mangostin α-mangostin constituents xanthones addition chemistry αmangostin, mangostin, family agents

The recommended treatment for latent tuberculosis (TB) infection in adults is a daily dose of isoniazid (INH) 300 mg for six months. In Brazil, INH was formulated as 100 mg tablets. The treatment duration and the high pill burden compromised patient adherence to the treatment. The Brazilian National Programme for Tuberculosis requested a new 300 mg INH formulation. The aim of our study was to compare the bioavailability of the new INH 300 mg formulation and three 100 mg tablets of the reference formulation. We conducted a randomised, single dose, open label, two-phase crossover bioequivalence study in 28 healthy human volunteers. The 90% confidence interval for the INH maximum concentration of drug observed in plasma and area under the plasma concentration vs. time curve from time zero to the last measurable concentration “time t” was 89.61-115.92 and 94.82-119.44, respectively. The main limitation of our study was that neither adherence nor the safety profile of multiple doses was evaluated. To determine the level of INH in human plasma, we developed and validated a sensitive, simple and rapid high-performance liquid chromatography-tandem mass spectrometry method. Our results showed that the new formulation was bioequivalent to the 100 mg reference product. This finding supports the use of a single 300 mg tablet daily strategy to treat latent TB. This new formulation may increase patients’ adherence to the treatment and quality of life.

A sensitive, accurate and simple method using HPLC-MS/MS was developed and validated for levodopa quantitation in human plasma. Analysis was achieved on a pursuit® C18 analytical column (5 µm; 150 x 4.6 mm i.d.) using a mobile phase (methanol and water , 90:10, v/v) containing formic acid 0.5% v/v, after extracting the samples using a simple protein plasma precipitation with perchloric acid. The developed method was validated in accordance with ANVISA guidelines and was successfully applied to a bioequivalence study in 60 healthy volunteers demonstrating the feasibility and reliability of the proposed method.